The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia

This study has been completed.

Study NCT00034749 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

First Received: May 2, 2002 Last Updated: June 6, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	March 2006
Estimated Primary Completion Date:	No date given

No publications provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, Pandina G, Kusumakar V. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009 Feb;194(2):158-64.